MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
Go back to MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity| (NASDAQ: MTVA) | Delayed: 1.67 -0.06 (3.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.73 | 52 Week High | $ | |||
| Open | $1.65 | 52 Week Low | $ | |||
| Day High | $1.70 | P/E | N/A | |||
| Day Low | $1.64 | EPS | $ | |||
| Volume | 45,290 | |||||

